Sanofi, BioNTech cut early-stage mRNA cancer therapy from pipeline
Sanofi and BioNTech scrapped development of an mRNA therapy that can be injected into a tumor after seeing results from an interim analysis.
Sanofi on Friday disclosed the development in its second quarter earnings report. The companies first partnered on a deal to develop cancer immunotherapies in 2015, and then in 2019, they put one candidate — SAR441000 — in a Phase I trial that enrolled 77 patients with advanced solid tumors, clinicaltrials.gov shows. The companies were testing the candidate as a monotherapy and as a combination treatment with Sanofi and Regeneron’s PD-1 checkpoint inhibitor Libtayo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.